| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
ALDERLEY PARK, U.K.—ApconiX, a nonclinical safety company working with the pharmaceutical sector, has achieved a fivefold sales increase in its second year of trading, far exceeding its predicted annual forecast. On top of that, the business recently received the accolade of Start-Up of the Year at the 17th awards hosted by BioNow, the northern England biomedical and life-sciences membership organization.
 
The company’s early success is based on delivering expertise in safety toxicology and ion channel electrophysiology to a changing pharmaceutical sector, in which more companies are outsourcing their essential drug safety testing and analysis, according to ApconiX.
 
Founded in 2015 by Prof. Ruth Roberts, Dr. Richard Knight and Dr. Michael Morton following many years working at AstraZeneca, ApconiX has already recruited a group of leading scientists with wide-ranging skills in preclinical drug safety. The company now has more than 60 clients across the United Kingdom, United States and Europe, including Pfizer, UCB and Gilead, as well as biotechs, startups and university spinouts. Current clients also include the U.S. Food and Drug Administration and the Institute for Cancer Research.
 
“We formed the company with a drive and ambition to create a world-renowned business known for nonclinical expertise supporting drug discovery and development. Since then, the take-up of our services has gone way beyond our expectations and includes companies, venture-capital funded organizations, charities and academia,” said Roberts, ApconiX director as well as co-founder. “Our cost-effective, flexible approach complements the way the pharmaceutical industry has evolved in recent years, with large pharma reducing its internal capability and outsourcing key skills to trusted partners. Meanwhile, there are many more pharma sector SMEs [small- to medium-sized enterprises] needing access to specialized services. That’s why we have established our own laboratory to help meet the market need for high-quality data.”
 
ApconiX is building a number of strategic alliances with organizations—for example, a close relationship with one local pharma company has led ApconiX to act as an outsourced safety department across its operations. ApconiX has also established several, strategic international alliances, including French company PhysioStim, therefore creating a European center of excellence for preclinical cardiovascular safety evaluation. Its recent alliance with Sygnature Discovery ensures the Nottingham-based contract research organization can provide its customers with a broader range of drug discovery services.
 
“Ultimately, our knowledge and expertise helps companies developing new drugs to make better decisions on drug safety,” said Roberts. “As identified in the government’s life sciences review [for 2016], drug discovery and development needs greater collaboration to de-risk the process and reduce the number of project failures caused by safety toxicity. The changing face of drug discovery and development means a safe pair of hands is needed to help companies navigate the difficult pathway towards safe, effective and profitable drugs.”

Related Topics

Published In

Volume 14 - Issue 1 | January 2018

January 2018

January 2018 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue